Advertisement

Impact of Granulocyte-colony Stimulating Factor on Bleomycin-induced Pneumonitis in Chemotherapy-treated Germ Cell Tumors

Published:September 04, 2017DOI:https://doi.org/10.1016/j.clgc.2017.08.012

      Abstract

      Objective

      To examine the impact of granulocyte-colony stimulating factor (G-CSF) use on the incidence and severity of bleomycin-induced pneumonitis (BIP) in patients with germ cell tumor (GCT) receiving first-line chemotherapy.

      Patients and Methods

      Clinical data from our institutional GCT database was complemented by review of radiology, pharmacy, and medical records. All patients receiving first line chemotherapy between January 1, 2000 and December 31, 2010 were included. Patients receiving at least 1 dose of G-CSF were identified. BIP was graded using Common Terminology Criteria for Adverse Events criteria. Logistic regression was used to explore predictors for risk and severity of BIP. Statistical significance was defined as P < .05.

      Results

      Data on 212 patients with GCT treated with a bleomycin-containing chemotherapy regimen were available. The median age was 31 years. The median follow-up period was 36.7 months. BIP occurred in 73 patients (34%), a majority (n = 55) of which were asymptomatic events (Common Terminology Criteria for Adverse Events, grade 1). G-CSF use was not associated with increased risk of BIP in multivariable analyses (odds ratio, 1.60; P = .13), nor was it associated with increased severity of symptomatic BIP (on average 1.22 grades higher; P = .09). There was a non-statistically significant trend towards greater risk of BIP in patients that developed renal impairment during chemotherapy treatment (odds ratio, 2.56; P = .053).

      Conclusion

      In patients with GCT receiving first line chemotherapy, G-CSF use is not associated with an increased risk of BIP. Furthermore, the use of G-CSF did not have any significant effect on the severity of BIP events. Clinicians are reminded to be vigilant of patients that develop renal impairment while undergoing chemotherapy treatment, given the greater risk of BIP.

      Keywords

      To read this article in full you will need to make a payment

      References

        • Feldman D.R.
        • Bosl G.J.
        • Sheinfeld J.
        • Motzer R.J.
        Medical treatment of advanced testicular cancer.
        JAMA. 2008; 299: 672-684
        • International Germ Cell Cancer Collaborative Group
        International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group.
        J Clin Oncol. 1997; 15: 594-603
        • Einhorn L.H.
        • Williams S.D.
        • Loehrer P.J.
        • et al.
        Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol.
        J Clin Oncol. 1989; 7: 387-391
        • Loehrer P.J.
        • Johnson D.
        • Elson P.
        • Einhorn L.H.
        • Trump D.
        Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial.
        J Clin Oncol. 1995; 13: 470-476
        • de Wit R.
        • Stoter G.
        • Kaye S.B.
        • et al.
        Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group.
        J Clin Oncol. 1997; 15: 1837-1843
        • Sikic B.I.
        Biochemical and cellular determinants of bleomycin cytotoxicity.
        Cancer Surv. 1986; 5: 81-91
        • Sleijfer S.
        Bleomycin-induced pneumonitis.
        Chest. 2001; 120: 617-624
        • O’Sullivan J.M.
        • Huddart R.A.
        • Norman A.R.
        • Nicholls J.
        • Dearnaley D.P.
        • Horwich A.
        Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours.
        Ann Oncol. 2003; 14: 91-96
        • Simpson A.B.
        • Paul J.
        • Graham J.
        • Kaye S.B.
        Fatal bleomycin pulmonary toxicity in the west of Scotland 1991-95: a review of patients with germ cell tumours.
        Br J Cancer. 1998; 78: 1061-1066
        • Toner G.C.
        • Stockler M.R.
        • Boyer M.J.
        • et al.
        Comparison of two standard chemotherapy regimens for good-prognosis germ-cell tumours: a randomised trial. Australian and New Zealand Germ Cell Trial Group.
        Lancet. 2001; 357: 739-745
        • Ngeow J.
        • Tan I.B.
        • Kanesvaran R.
        • et al.
        Prognostic impact of bleomycin-induced pneumonitis on the outcome of Hodgkin’s lymphoma.
        Ann Hematol. 2011; 90: 67-72
        • Wilson-Royalty M.
        • Lawless G.
        • Palmer C.
        • Brown R.
        Predictors for chemotherapy-related severe or febrile neutropenia: a review of the clinical literature.
        J Oncol Pharm Pract. 2001; 7: 141-147
        • Grimison P.S.
        • Stockler M.R.
        • Thomson D.B.
        • et al.
        Comparison of two standard chemotherapy regimens for good-prognosis germ cell tumors: updated analysis of a randomized trial.
        J Natl Cancer Inst. 2010; 102: 1253-1262
        • Thibault C.
        • Fizazi K.
        • Barrios D.
        • et al.
        Compliance with guidelines and correlation with outcome in patients with advanced germ-cell tumours.
        Eur J Cancer. 2014; 50: 1284-1290
        • National Comprehensive Cancer Network
        Myeloid Growth Factors (Version 1.2017) [Internet].
        2017 (Available at:) (Accessed: August 25, 2017)
        • Smith T.J.
        • Khatcheressian J.
        • Lyman G.H.
        • et al.
        2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.
        J Clin Oncol. 2006; 24: 3187-3205
        • Aapro M.S.
        • Bohlius J.
        • Cameron D.A.
        • et al.
        2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.
        Eur J Cancer. 2011; 47: 8-32
        • Matthews J.H.
        Pulmonary toxicity of ABVD chemotherapy and G-CSF in Hodgkin’s disease: possible synergy.
        Lancet. 1993; 342: 988
        • Dirix L.Y.
        • Schrijvers D.
        • Druwè P.
        • Van den Brande J.
        • Verhoeven D.
        • Van Oosterom A.T.
        Pulmonary toxicity and bleomycin.
        Lancet. 1994; 344: 56
        • Martin W.G.
        • Ristow K.M.
        • Habermann T.M.
        • Colgan J.P.
        • Witzig T.E.
        • Ansell S.M.
        Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin’s lymphoma.
        J Clin Oncol. 2005; 23: 7614-7620
        • Minuk L.A.
        • Monkman K.
        • Chin-Yee I.H.
        • et al.
        Treatment of Hodgkin lymphoma with adriamycin, bleomycin, vinblastine and dacarbazine without routine granulocyte-colony stimulating factor support does not increase the risk of febrile neutropenia: a prospective cohort study.
        Leuk Lymphoma. 2012; 53: 57-63
        • Evens A.M.
        • Cilley J.
        • Ortiz T.
        • et al.
        G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis.
        Br J Haematol. 2007; 137: 545-552
        • Fosså S.D.
        • Kaye S.B.
        • Mead G.M.
        • et al.
        Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party.
        J Clin Oncol. 1998; 16: 716-724
        • Saxman S.B.
        • Nichols C.R.
        • Einhorn L.H.
        Pulmonary toxicity in patients with advanced-stage germ cell tumors receiving bleomycin with and without granulocyte colony stimulating factor.
        Chest. 1997; 111: 657-660
        • Ahmed B.M.
        • Al-Zakwani I.S.
        Incidence, outcome and predictors of bleomycin pulmonary toxicity in a university hospital in Oman.
        J Oncol Pharm Pract. 2013; 19: 3-7
        • Feldman D.
        • Vander Els N.
        Bleomycin-induced lung injury [Internet]. UpToDate.
        2016 (Available at:) (Accessed: January 8, 2017)
        • Kawai K.
        • Hinotsu S.
        • Tomobe M.
        • Akaza H.
        Serum creatinine level during chemotherapy for testicular cancer as a possible predictor of bleomycin-induced pulmonary toxicity.
        Jpn J Clin Oncol. 1998; 28: 546-550
        • Lauritsen J.
        • Kier M.G.G.
        • Bandak M.
        • et al.
        Pulmonary function in patients with germ cell cancer treated with bleomycin, etoposide, and cisplatin.
        J Clin Oncol. 2016; 34: 1492-1499
        • Reinert T.
        • Baldotto C.
        • Nunes F.
        • Scheliga A.
        Bleomycin-induced lung injury.
        J Cancer Res. 2013; 2013: 1-9
        • Adachi K.
        • Suzuki M.
        • Sugimoto T.
        • et al.
        Effects of granulocyte colony-stimulating factor (G-CSF) on bleomycin-induced lung injury of varying severity.
        Toxicol Pathol. 2003; 31: 665-673
        • Azoulay E.
        • Herigault S.
        • Levame M.
        • et al.
        Effect of granulocyte colony-stimulating factor on bleomycin-induced acute lung injury and pulmonary fibrosis.
        Crit Care Med. 2003; 31: 1442-1448
        • Azoulay E.
        • Attalah H.
        • Harf A.
        • Schlemmer B.
        • Delclaux C.
        Granulocyte colony-stimulating factor or neutrophil-induced pulmonary toxicity: myth or reality? Systematic review of clinical case reports and experimental data.
        Chest. 2001; 120: 1695-1701
        • Tate R.M.
        • Repine J.E.
        Neutrophils and the adult respiratory distress syndrome.
        Am Rev Respir Dis. 1983; 128: 552-559
        • McKeage M.J.
        • Evans B.D.
        • Atkinson C.
        • Perez D.
        • Forgeson G.V.
        • Dady P.J.
        Carbon monoxide diffusing capacity is a poor predictor of clinically significant bleomycin lung. New Zealand Clinical Oncology Group.
        J Clin Oncol. 1990; 8: 779-783
        • Roncolato F.T.
        • Chatfield M.
        • Houghton B.
        • et al.
        The effect of pulmonary function testing on bleomycin dosing in germ cell tumours.
        Int Med J. 2016; 46: 893-898